NXTC
NextCure, Inc. NASDAQ Listed May 9, 2019$10.18
Mkt Cap $27.3M
52w Low $4.44
50.8% of range
52w High $15.74
50d MA $11.25
200d MA $9.70
P/E (TTM)
-0.5x
EV/EBITDA
-0.3x
P/B
0.8x
Debt/Equity
0.1x
ROE
-159.8%
P/FCF
-0.8x
RSI (14)
—
ATR (14)
—
Beta
1.58
50d MA
$11.25
200d MA
$9.70
Avg Volume
49.6K
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
9000 Virginia Manor Road · Beltsville, MD 20705 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -2.26 | -0.81 | +64.2% | 12.76 | -0.2% | -2.9% | -2.0% | -0.4% | +6.6% | +6.0% | — |
| Nov 5, 2025 | AMC | -4.06 | -3.22 | +20.7% | 9.63 | -1.1% | +2.0% | -7.0% | -11.7% | -11.5% | -3.5% | — |
| Aug 7, 2025 | AMC | -4.62 | -11.29 | -144.4% | 5.10 | -3.7% | -4.5% | -5.9% | -5.1% | +1.8% | +1.0% | — |
| May 1, 2025 | AMC | -4.80 | -4.68 | +2.5% | 5.76 | -2.1% | -7.8% | -6.2% | -8.3% | -20.8% | -19.8% | — |
| Mar 6, 2025 | AMC | -4.08 | -4.92 | -20.6% | 8.55 | +4.1% | +5.3% | +3.2% | -2.7% | +1.1% | +1.1% | — |
| Nov 7, 2024 | AMC | -4.20 | -4.92 | -17.1% | 15.84 | +2.3% | -2.3% | +3.0% | +16.7% | +6.8% | +1.5% | — |
| Aug 1, 2024 | AMC | -4.32 | -6.60 | -52.8% | 19.32 | -5.0% | -0.6% | -6.2% | -1.9% | -4.3% | -3.1% | — |
| May 2, 2024 | AMC | -5.40 | -7.32 | -35.6% | 17.88 | +7.4% | +2.7% | +10.7% | +6.0% | +6.0% | +15.4% | — |
| Mar 21, 2024 | AMC | -6.48 | -6.24 | +3.7% | 20.16 | +4.2% | +13.1% | +18.5% | +17.3% | +15.5% | +32.7% | — |
| Nov 2, 2023 | AMC | -7.68 | -6.12 | +20.3% | 14.04 | +0.0% | +0.9% | +0.0% | -2.6% | -3.4% | -8.5% | — |
| Aug 3, 2023 | AMC | -7.20 | -7.68 | -6.7% | 20.64 | -2.9% | -1.2% | -1.2% | -0.6% | -1.7% | +0.6% | — |
| May 4, 2023 | AMC | -7.68 | -6.96 | +9.4% | 19.08 | +0.6% | +0.0% | +1.9% | +9.4% | +10.1% | +11.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 7 | Ladenburg Thalmann | Upgrade | Neutral → Buy | — | $9.82 | $9.97 | +1.5% | -8.8% | -13.4% | -13.2% | -5.4% | -0.6% |
| Jul 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.90 | $4.82 | -1.6% | -2.9% | -1.6% | +4.7% | +1.8% | +1.6% |
| Jul 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.52 | $5.49 | -0.5% | -5.3% | -6.9% | -5.3% | -4.2% | -0.9% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.27 | $8.40 | +1.6% | -7.0% | -16.1% | -16.0% | -10.9% | -17.3% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.55 | $8.90 | +4.1% | +5.3% | +3.2% | -2.7% | +1.1% | +1.1% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.48 | $16.80 | +8.5% | +5.4% | +19.4% | +9.3% | +3.9% | +1.6% |
| Aug 2 | Needham | Maintains | Buy → Buy | — | $19.32 | $18.36 | -5.0% | -0.6% | -6.2% | -1.9% | -4.3% | -3.1% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.48 | $18.96 | +2.6% | -9.1% | -12.3% | -10.4% | -20.1% | -9.7% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.96 | $19.20 | +1.3% | -2.5% | -11.4% | -14.6% | -12.7% | -22.2% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.88 | $19.20 | +7.4% | +2.7% | +10.7% | +6.0% | +6.0% | +15.4% |
| May 3 | Needham | Maintains | Buy → Buy | — | $17.88 | $19.20 | +7.4% | +2.7% | +10.7% | +6.0% | +6.0% | +15.4% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.16 | $21.00 | +4.2% | +13.1% | +18.5% | +17.3% | +15.5% | +32.7% |
| Mar 20 | Needham | Maintains | Buy → Buy | — | $17.16 | $17.52 | +2.1% | -1.4% | +17.5% | +32.9% | +39.2% | +37.8% |
| Dec 14 | Needham | Maintains | Buy → Buy | — | $17.40 | $12.84 | -26.2% | -19.3% | -23.4% | -22.8% | -18.6% | -21.4% |
| Aug 4 | Needham | Maintains | Buy → Buy | — | $20.64 | $20.04 | -2.9% | -1.2% | -1.2% | -0.6% | -1.7% | +0.6% |
| May 5 | Needham | Maintains | Buy → Buy | — | $19.08 | $19.20 | +0.6% | +0.0% | +1.9% | +9.4% | +10.1% | +11.9% |
| Mar 3 | Needham | Maintains | Buy → Buy | — | $18.84 | $18.96 | +0.6% | -4.5% | -2.5% | -5.1% | -4.5% | -6.4% |
| Nov 4 | Needham | Maintains | Buy → Buy | — | $30.12 | $29.64 | -1.6% | -21.1% | -31.9% | -32.3% | -35.9% | -33.1% |
| Nov 4 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | $30.12 | $29.64 | -1.6% | -21.1% | -31.9% | -32.3% | -35.9% | -33.1% |
| Nov 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $30.12 | $29.64 | -1.6% | -21.1% | -31.9% | -32.3% | -35.9% | -33.1% |
| Aug 23 | Truist | Maintains | Buy → Buy | — | $54.12 | $54.12 | +0.0% | -1.6% | -0.2% | -0.2% | -2.4% | -5.3% |
| May 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $45.48 | $45.36 | -0.3% | -1.3% | -6.6% | -6.9% | -4.2% | +5.3% |
| Mar 1 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $58.80 | $59.76 | +1.6% | +0.4% | -1.4% | -2.4% | -2.9% | -2.7% |
| Nov 5 | Needham | Maintains | Buy → Buy | — | $104.64 | $99.00 | -5.4% | -1.3% | -6.2% | -23.4% | -25.6% | -24.1% |
| Mar 5 | Truist | Upgrade | Hold → Buy | — | $136.68 | $145.20 | +6.2% | -0.7% | -3.7% | +3.4% | +4.5% | +5.6% |
| Jan 15 | BofA Securities | Downgrade | Neutral → Underperform | — | $156.84 | $146.64 | -6.5% | -5.8% | -6.7% | -0.8% | -3.6% | +4.1% |
| Jul 16 | Benchmark | Upgrade | Hold → Buy | — | $108.12 | $114.36 | +5.8% | +3.3% | +2.6% | +3.1% | +3.1% | +7.3% |
| Jul 14 | BTIG | Maintains | Buy → Buy | — | $97.80 | $100.80 | +3.1% | +11.4% | +10.6% | +14.2% | +13.4% | +14.0% |
| Jul 13 | SunTrust Robinson Humphrey | Downgrade | Buy → Hold | — | $214.56 | $153.00 | -28.7% | -54.4% | -49.2% | -49.6% | -47.9% | -48.3% |
| Jun 1 | Benchmark | Downgrade | Buy → Hold | — | $374.52 | $364.32 | -2.7% | -4.3% | -8.1% | -13.9% | -16.1% | -18.4% |
| May 8 | Morgan Stanley | Maintains | Overweight → Overweight | — | $430.68 | $444.24 | +3.1% | +5.8% | +5.3% | -1.9% | -7.0% | -3.1% |
| Apr 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $458.16 | $457.68 | -0.1% | -8.6% | -9.1% | -2.7% | -3.6% | -5.3% |
| Mar 2 | Roth Capital | Maintains | Buy → Buy | — | $501.12 | $510.36 | +1.8% | +2.6% | -1.6% | +4.0% | +3.8% | +1.7% |
| Jan 13 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $680.40 | $687.60 | +1.1% | -8.3% | -6.1% | -6.0% | -6.7% | -11.6% |
| Dec 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $620.28 | $621.96 | +0.3% | +1.5% | -3.0% | +6.4% | +13.3% | +27.7% |
| Nov 26 | BTIG | Maintains | Buy → Buy | — | $478.08 | $489.60 | +2.4% | +0.3% | +2.8% | +20.0% | +9.4% | +18.5% |
| Nov 13 | Morgan Stanley | Maintains | Overweight → Overweight | — | $448.92 | $426.12 | -5.1% | +0.9% | +3.0% | -3.6% | -2.8% | -3.8% |
| Nov 12 | Bank of America | Maintains | Buy → Buy | — | $468.24 | $467.88 | -0.1% | -4.1% | -3.3% | -1.2% | -7.6% | -6.8% |
| Sep 9 | Bank of America | Maintains | Buy → Buy | — | $412.08 | $415.20 | +0.8% | +2.9% | +7.0% | +7.2% | +9.7% | +7.9% |
| Sep 5 | Piper Jaffray | Maintains | Overweight → Overweight | — | $473.16 | $485.88 | +2.7% | +5.5% | -12.9% | -10.4% | -6.8% | -6.7% |
| Sep 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $473.16 | $485.88 | +2.7% | +5.5% | -12.9% | -10.4% | -6.8% | -6.7% |
| Aug 13 | Morgan Stanley | Maintains | Overweight → Overweight | — | $290.88 | $299.04 | +2.8% | +10.2% | +2.7% | +6.2% | +9.6% | +10.6% |
| Jul 9 | Bank of America | Maintains | Buy → Buy | — | $188.76 | $191.88 | +1.7% | +7.8% | +5.8% | +8.1% | +6.7% | +5.3% |
| Jun 3 | Piper Jaffray | Maintains | Overweight → Overweight | — | $223.44 | $226.68 | +1.5% | -6.8% | -4.9% | -12.7% | -10.6% | -11.0% |
| Jun 3 | Morgan Stanley | Maintains | Overweight → Overweight | — | $223.44 | $226.68 | +1.5% | -6.8% | -4.9% | -12.7% | -10.6% | -11.0% |
No insider trades available.
Data updated apr 26, 2026 4:37pm
· Source: massive.com